



1614  
#8

Practitioner's Docket No.

2605/102

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 28 2003

RECEIVED CENTER 1600/2900

Patent application  
of \_\_\_\_\_

Inventor(s)

for \_\_\_\_\_

Title of invention

OR

In re application of: Toshio Miyata

Application No.: 10/009,877

Group No.:

1614

Filed: November 13, 2001

Examiner:

Not Yet Assigned

For: Blood Carbonyl Compound-Trapping Agent

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
WITHIN THREE MONTHS OF FILING OR  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. SECTION 1.97(b))

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. SECTION 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

FACSIMILE

[x] deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope  
addressed to Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450

[ ] transmitted by facsimile to the Patent and Trademark  
Office.

Date: August 25, 2003

Signature

Barbara J. Carter, Ph.D.

(type or print name of person certifying)

(Transmittal of Information Disclosure Statement Within Three Months of Filing or Before Mailing of First Office Action--page

1 of 3)

RECEIVED

DEC 11 2003

OFFICE OF PETITIONS

*NOTE:* "An information disclosure statement shall be considered by the Office if filed by the applicant: (1) within three months of the filing date of a national application; (2) within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or (3) before the mailing date of a first Office action on the merits, whichever event occurs last." 37 C.F.R. section 1.97(b).

*NOTE:* The "filing date of a national application" under 37 C.F.R. section 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. section 1.53(b) as "the date on which: (1) A specification containing a description pursuant to section 1.71 and at least one claim pursuant to section 1.75; and (2) any drawing required by section 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by section 1.41." 37 C.F.R. section 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. section 371(c) within the periods set forth in section 1.494 or section 1.495. 35 U.S.C. section 371(c) requires the filing of the following: (1) the basic national fee; (2) a copy of the international application, unless already sent by the International Bureau, and optionally an English translation if filed in another language; and, also optionally (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. The optional items must be submitted later, with surcharges. 37 C.F.R. section 1.97(b)(2).

#### **IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

*NOTE:* "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

*NOTE:* "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

*NOTE:* "The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

*NOTE:* "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirement (37 C.F.R. section 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. section 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

**WARNING:** "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. section 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

  
\_\_\_\_\_  
SIGNATURE OF PRACTITIONER

Reg. No. 52,703

Barbara J. Carter, Ph.D.  
(type or print name of practitioner)

Tel. No.: (617) 443-9292

125 Summer Street, 11<sup>th</sup> Floor

P.O. Address

Customer No.: 002101

Boston, MA 02110

02605/00103 266554.1



Practitioner's Docket No.

2605/102

RECEIVED  
PATENT

AUG 28 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application

of \_\_\_\_\_

Inventor(s)

for \_\_\_\_\_

Title of invention

the specification of which is being transmitted herewith

OR

In re application of: Toshio Miyata

Application No.: 10/009,877

Group No.:

1614

Filed: November 13, 2001

Examiner:

Not Yet Assigned.

For: Blood Carbonyl Compound-Trapping Agent

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

(Information Disclosure Statement--page 1 of 9)

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

*(When using Express Mail, the Express Mail label number is mandatory;*

*Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"

Mailing Label No. \_\_\_\_\_ (mandatory)

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: August 25, 2003

Barbara J. Carter, Ph.D.

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).

"Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable C.F.R.e. requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

RECEIVED

DEC 11 2003

OFFICE OF PETITIONS



## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

RECEIVED

AUG 28 2003

TECH CENTER 1500/2200

**NOTE:**

"An information disclosure statement shall be considered by the Office if filed by the applicant:

- (1) Within three months of the filing date of a national application;
- (2) Within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or
- (3) Before the mailing date of a first Office action on the merits, whichever event occurs last." 37 C.F.R. section 1.97(b).

**NOTE:**

"Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section." 37 C.F.R. section 1.56(a).

"Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) each inventor named in the application;
- (2) each attorney or agent who prepares or prosecutes the application; and
- (3) every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application." 37 C.F.R. section 1.56(c).

**NOTE:**

The "duty as described in section 1.56 will be met so long as the information in question was cited by the Office or submitted to the Office in the manner prescribed by sections 1.97(b) - (d) and 1.98 before issuance of the patent." Notice of January 9, 1992, 1135 O.G. 13-25 at 17.

**WARNING:** "No information disclosure statement may be filed in a provisional application." 37 C.F.R. section 1.51(b).

### List of Sections Forming Part of This Supplemental Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

(check sections forming a part of this statement: disC.F.R.d unused sections and number pages consecutively)

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
3. ☐ Statement as to Information Not Found in Patents or Publications
4. ☐ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted
5. ☐ Cumulative Patents or Publications
6. ☒ Copies of Listed Information Items Accompanying This Statement
7. ☐ Concise Explanation of Non-English Language Listed Information Items
  - 7A. ☐ JEPO Search Report
  - 7B. ☐ English Language Version of EPO Search Report
8. ☒ Translation(s) of Non-English Language Documents
9. ☐ Concise Explanation of English Language Listed Information Items (Optional)
10. ☒ Identification of Person(s) Making This Information Disclosure Statement

(complete the following, if appropriate)

Sections \_\_\_\_\_, respectively, have been continued on ADDED PAGE(S).


**NOTE:** "Once the minimum requirements are met, the examiner has an obligation to consider the information." Notice of April 20, 1992 (1138 O.G. 37-41, 37).

(Information Disclosure Statement--page 2 of 9)

RECEIVED

DEC 11 2003

OFFICE OF PETITIONS



### Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware, that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

RECEIVED  
AUG 28 2003  
TECHNICAL CENTER

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.



## SECTION 2. FORMS PTO/SB/08A and 08B (formerly Form PTO-1449)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Toshio Miyata

Attorney Docket: 2605/102

Serial No: 10/009,877

Art Group Unit: 1614

Date Filed: November 13, 2001

Examiner Name: Not Yet Assigned.

Invention: Blood Carbonyl Compound-Trapping Agent

RECEIVED

AUG 28 2003

TECH CENTER 1600/2900

LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS					
Examiner Initials	Reference Number	Document Number	Issue Date	Inventor	Class/Subclass
	AN	US4,977,287	12/11/90	Kakimoto, et al.	556/83


FOREIGN PATENT DOCUMENTS						
Exam. Initials	Ref. No.	Country Code	Doc. No.	Public. Date	Patentee or Applicant	Class/Subclass
	AO	JP	62-142114, A <i>*See Ref. No. DC for Corresponding EP Appln.</i>	6/25/87	Cerami, A., et al.	A61K31/155
	AP	JP	62-249908, A	10/30/87	Fujimoto, D., et al.	A 61K 7/00
	AQ	JP	64-056614, A	3/3/89	Ouchida, S., et al.	A 61K 31/155
	AR	JP	64-083059, A	3/28/89	Ouchida, S., et al.	C07C143/72
	AS	JP	2-156, A <i>*See Ref. No. DD for Corresponding EP Appln.</i>	1/5/90	Cerami, A., et al.	C07281/16
	AT	JP	2-765, A	1/5/90	Ouchida, S., et al.	C07C281/16
	AU	JP	2-42053, A <i>*See Ref. No. DE for Corresponding EP Appln.</i>	2/13/90	Ouchida, S., et al.	C07C281/16
	AV	JP	6-9380	1/18/94	Williamson, J.R., et al.	A61K 31/155
	AW	JP	10-167965, A	6/23/98	Yasumura, K., et al.	A61K 31/415
	AX	JP	6-192089, A	7/12/94	Niigata, K., et al.	A61K 31/41
	AY	JP	6-298737, A	10/25/94	Niigata, K., et al.	C07D231/14
	AZ	JP	6-298738, A	10/25/94	Niigata, K., et al.	C07D231/38
	BA	JP	5-201993	8/10/93	Miyajima, K., et al.	C07D233/88
	BB	JP	6-135968, A	5/17/94	Kurono, M., et al.	C07D491/107
	BC	JP	7-133264, A	5/23/95	Yasumura, K., et al.	C07D233/88
	BD	JP	10-182460, A	7/7/98	Hotta, A., et al.	A61K 31/415
	BE	JP	4-9375, A	1/14/92	Soda, T., et al.	C07D277/48
	BF	JP	9-59258, A	3/4/97	Matsui, T., et al.	C07D233/88
	BG	JP	3-261772, A	11/21/91	Sumoto, K., et al.	C07D277/06
	BH	JP	8-157473, A <i>*See Ref. No. DF for Corresponding WO Appln.</i>	6/18/96	Ohara, Y., et al.	C07D417/06

(Information Disclosure Statement--page 4 of 9)

RECEIVED

DEC 11 2003

OFFICE OF PETITIONS



RECEIVED

AUG 28 2003

BI	JP	10-158244, A	6/16/98	Iyobe, A., et al.	C07D213/65
BJ	JP	10-175954, A	6/30/98	Iyobe, A., et al.	C07D213/65
BK	JP	6-287180, A	10/11/94	Niigata, K., et al.	C07D213/65
BL	JP	6-305964	11/1/94	Yasumura, K., et al.	A61K 31/415
BM	JP	3-161441, A *See Ref. No. DG for Corresponding EP Appln.	7/11/91	Inoue, J.	A61K31/47
BN	JP	7-196498, A	8/1/95	Zuckerman, S.H.	A61K31/40
BO	JP	3-204874, A	9/6/91	Ouchida, S., et al.	C07D311/72
BP	JP	4-308586, A	10/30/92	Ouchida, S., et al.	C07D311/04
BQ	JP	2-167264, A *See Ref. No. DH for Corresponding EP Appln.	6/27/90	Soda, T., et al.	C07D213/74
BR	JP	3-148220, A	6/25/91	Kurozumi, M., et al.	A61K 31/41
BS	JP	5-9114, A	1/19/93	Hayakawa, M., et al.	A61K 31/12
BT	JP	5-310565 A	11/22/93	Ulrich, P.C., et al.	A61K 31/16
BU	JP	62-249909, A *See Ref. No. DI for Corresponding EP Appln.	10/30/87	Nagaoka, Y., et al.	A61K7/00
BV	JP	2-62885, A *See Ref. No. AN for Corresponding US Patent	3/2/90	Kakimoto, N., et al	C07F7/30
BW	JP	5-255130, A	10/5/93	Kakimoto, N., et al	C07B63/04
BX	JP	7-247296, A	9/26/95	Kakimoto, N., et al	C07F7/30
BY	JP	8-59485, A	3/5/96	Sawai, K., et al.	A61K31/80
BZ	JP	3-240725, A	10/28/91	Morisake, M., et al	A61K31/35
CA	JP	7-206838, A	8/8/95	Hosokawa, T.,	C07D307/32
CB	JP	9-241165, A	9/16/97	Takahashi, H., et al.	A61K31/70
CC	WO	94/04520 A1	3/3/94	Hosokawa, T.,	C07D307/32
CD	JP	6-206818, A	7/26/94	Schoenafinger, K., et al.	A61K31/425
CE	JP	9-59233, A	3/4/97	Sato, F., et al.	C07C229/36
CF	JP	9-40626, A	2/10/97	Sato, F., et al.	C07C237/20
CG	JP	9-124471, A	5/13/97	Sato, F., et al.	A61K31/135
CH	JP	6-305959	11/1/94	Hosokawa, T.,	A61K31/19
CI	WO	91/11997, A1	8/22/91	Inoue, J.	A61K31/195
CJ	JP	10-158265, A	6/16/98	Nakazawa, Y., et al.	C07D471/16
CK	WO	97/09981 A1	3/20/97	Hudson, B.G., et al	A61K31/425
CL	JP	6-256280, A	9/13/94	Golub, L.M., et al.	C07C237/26
CM	JP	9-221427, A	8/26/97	Ito, M.	A61K31/73
CN	JP	9-40519, A	2/10/97	Uchino, K., et al.	A61K7/00
CO	JP	20753, A	1/5/90	Ouchida, S., et al.	C07C243/28
CP	JP	5-505189, A *See Ref. No. CX for Corresponding WO Appln.	8/5/93	Meglason, M.D.	A61K31/19
CQ	JP	7-500811, A *See Ref. No. CY for Corresponding WO Appln.	1/26/95	Ulrich, P.C., et al.	C07D239/42
CR	JP	4-502611, A *See Ref. No. CZ Corresponding WO Appln.	5/14/92	Grigg, G.W., et al.	A61K37/02
CS	JP	7-503713, A *See Ref. No. DA for Corresponding WO Appln.	4/20/95	Ulrich, P.C., et al.	A61K31/195
CT	JP	7-500580, A *See Ref. No. DB for Corresponding WO Appln.	1/19/95	Michaelis, J., et al.	A61K38/00

(Information Disclosure Statement--page 5 of 9)

RECEIVED

DEC 11 2003

OFFICE DE BREVETS





RECEIVED

AUG 28 2003

TECHNICAL CENTER 1503/2303

	CU	JP	9-315960, A.	12/9/97	Mizuno, T., et al.	A61K31/12
	CV	JP	6-287179, A	10/11/94	Niigata, K., et al.	C07D271/08
	CW	EP	0474874, A1	3/18/92	Inoue, J.	A61K31/195
	CX	WO	91/12800, A1	9/5/91	Meglasson, M.D.	A61K31/195
	CY	WO	92/11853, A1	7/23/92	Ulrich, P.C., et al.	A61K31/505
	CZ	WO	90/06102, A1	6/14/90	Grigg, G.W., et al.	A61K7/40
	DA	WO	93/14750, A1	8/5/93	Ulrich, P.C., et al.	A61K31/195
	DB	WO	93/04690, A1	3/18/93	Michaelis, J., et al.	A61K37/02
	DC	EP	0222313, A2	5/20/87	Cerami, A., et al.	A61K31/55
	DD	EP	0316852, A2	5/24/89	Ulrich, P.C., et al.	A61K31/155
	DE	EP	0339496, A2	11/2/89	Ohuchida, S., et al. [sic]	C07C133/10
	DF	WO	96/11196, A1	4/18/96	Ohara, Y., et al.	C07D417/14
	DG	EP	0433679, A2	6/26/91	Inoue, J.	A61K31/535
	DH	EP	0359112, A2	3/21/90	Sohda, T., et al.	C07D277/42
	DI	EP	0242855, A2	10/28/87	Nagaoka, Y., et al.	A61K7/48

## OTHER DOCUMENTS

Exam. Initials	Ref. No.	Author	Title of Article, Title of Journal, Volume Number, Page Numbers, Date
	DJ	Miyata, T., et al.	Implication of an Increased Oxidative Stress in the Formation of Advanced Glycation End Products in Patients with End-Stage Renal Failure, <i>Kidney International</i> , Vol. 31 (1997) pp. 1170-1181
	DK	Foote, E.F., et al.	The Pharmacokinetics of Aminoguanidine in End-Stage Renal Disease Patients on Hemodialysis, <i>American Journal of Kidney Disease</i> , Vol. 25, No. 3 (March) 1995: pp. 420-425
	DL	Nakamura, S., et al.	Progression of Nephropathy in Spontaneous Diabetic Rats is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation, <i>Diabetes</i> , Vol. 46, May 1997, pp 895-899
	DM	Rahbar, S.	An Abnormal Hemoglobin in Red Cells of Diabetics, <i>Clin. Chim. Acta.</i> , 22 (1968) 296-298
	DN	Miyata T., et al.	Accumulation of Albumin-Linked and Free-Form Pentosidine in the Circulation of Uremic Patients with End-Stage Renal Failure: Renal Implications in the Pathophysiology of Pentosidine, <i>Journ. of the Amer. Society of Nephrology</i> , Vol. 7, Number 8, 1996
	DO	Maillard L.-C.	Reaction Generale Des Acides Amines Sur Les Sucres: Ses Consequences Biologiques, <i>Societe de Biologie</i> , April 20, p. 599-603

Examiner Signature: \_\_\_\_\_

Date Considered: \_\_\_\_\_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *if not* in conformance and not considered. Include copy of this form with next communication to applicant.

(Information Disclosure Statement--page 6 of 9)

RECEIVED

DEC 11 2003

OFFICE OF PETITIONS

## Section 6. Copies of Listed Information Items Accompanying This Statement

*NOTE: 37 C.F.R. section 1.98(a)(2) requires that any information disclosure statement filed under section 1.97 shall include: "A legible copy of: (i) Each U.S. and foreign patent; (ii) Each publication or that portion which caused it to be listed; and (iii) All other information or that portion which caused it to be listed, except that no copy of a U.S. patent application need be included..."*

*NOTE: The wording in section 1.98(a)(2)(iii) makes it clear that the requirement to submit a copy of each item of information listed in an information disclosure statement does not apply to the citation of a U.S. patent application. Notice of January 9, 1992, 1135 O.G. 13-25, at 14.*

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

*(complete the following, if applicable)*

☐ Exception(s) to above:

☐ Items in prior application, from which an earlier filing date is claimed for this application, as identified in Section 4.

☐ Cumulative patents or publications identified in Section 5.

## Section 8. Translation(s) of Non-English Language Documents

**NOTE:** "If a written English language translation of a non-English language document, or portion thereof, is within the possession, custody or control of, or is readily available to any individual designated in section 1.56(c), a copy of the translation shall accompany the statement." 37 C.F.R. section 1.98(c).

**NOTE:** "The Office does not intend to require translations unless they have been reduced to writing and are actually translations of what is contained in the non-English language information. Applicants should note, however, that most examiners do not have the ability to understand information which is not in English and that the Office will not routinely translate information submitted in a non-English language. The examiner will consider the information insofar as it is understood on its face, e.g., drawings, chemical formulas, English language abstracts, but will not have the information translated unless it appears to be necessary to do so. Applicants are required to aid the examiner by complying with the requirements for a concise explanation in section 1.98(a)(3) for information submitted in a non-English language." Notice of January 9, 1992, 1135 O.G. 13-25, at 21.

**NOTE:** "The examiner will indicate that the non-English language information has been considered in the same manner as consideration is indicated for information submitted in English." Notice of April 20, 1992 (1138 O.G. 37-41, 41).

- ☒ Submitted herewith is an English translation of the following foreign language patents, publications or information or of those portions of those patents, publications or information considered to be material: **DO**

*(complete the following, if applicable)*

- ☐ No English language translations of the foreign language patents, publications or information or parts thereof are readily available, except for those listed above.
- ☒ The following foreign language documents submitted are believed to be the equivalent or substantial equivalent of the English language documents identified below, which are also submitted herewith.

Foreign	English
AO	DC (EP Application)
AS	DD (EP Application)
AU	DE (EP Application)
BH	DF (WO Application)
BM	DG (EP Application)
BQ	DH (EP Application)
BU	DI (EP Application)
BV	AN (US Application)
CP	CX (PCT Application)
CQ	CY (PCT Application)
CR	CZ (PCT Application)
CS	DA (PCT Application)
CT	DB (PCT Application)

(Information Disclosure Statement--page 8 of 9)

**RECEIVED**

DEC 11 2003

**OFFICE OF PETITIONS**

**Section 10. Identification of Person(s) Making This Supplemental Information Disclosure Statement**

The person making this certification is

*(check each applicable item)*

- (a) ☐ the inventor(s) who signs below

\_\_\_\_\_  
**SIGNATURE OF INVENTOR**

\_\_\_\_\_  
*(type name of inventor who is signing)*

- (b) ☐ an individual associated with the filing and prosecution of this application (37 C.F.R. section 1.56(c))

\_\_\_\_\_  
**SIGNATURE OF INVENTOR**

\_\_\_\_\_  
*(type name of inventor who is signing)*

- (c) ☒ the practitioner who signs below on the basis of the information:

*(check each applicable item)*

☐ supplied by the inventor(s).

☐ supplied by an individual associated with the filing and prosecution of this application. (37 C.F.R. section 1.56(c)).


☒ in the practitioner's file.

Reg. No.: 52,703

Tel. No.: (617) 443-9292

Customer No.: 002101

02605/00102 266503.1

  
\_\_\_\_\_  
**SIGNATURE OF PRACTITIONER**

**Barbara J. Carter, Ph.D.**

\_\_\_\_\_  
*(type or print name of practitioner)*

**125 Summer Street, 11<sup>th</sup> Floor**

\_\_\_\_\_  
P.O. Address

**Boston, MA 02110**